Technical Analysis for ALLR - Allarity Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.77 | 4.64% | 0.03 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 4.64% | |
| Calm After Storm | Range Contraction | 4.64% | |
| Narrow Range Bar | Range Contraction | 4.64% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 10 hours ago |
| Possible NR7 | about 12 hours ago |
| Possible Inside Day | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Down 2 % | about 15 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/15/2023
Allarity Therapeutics, Inc. Description
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 366.32 |
| 52 Week Low | 0.71 |
| Average Volume | 3,389,118 |
| 200-Day Moving Average | 14.35 |
| 50-Day Moving Average | 4.51 |
| 20-Day Moving Average | 1.41 |
| 10-Day Moving Average | 1.15 |
| Average True Range | 0.52 |
| RSI (14) | 11.50 |
| ADX | 38.54 |
| +DI | 36.58 |
| -DI | 23.18 |
| Chandelier Exit (Long, 3 ATRs) | 3.53 |
| Chandelier Exit (Short, 3 ATRs) | 2.27 |
| Upper Bollinger Bands | 2.20 |
| Lower Bollinger Band | 0.63 |
| Percent B (%b) | 0.09 |
| BandWidth | 110.88 |
| MACD Line | -1.01 |
| MACD Signal Line | -1.14 |
| MACD Histogram | 0.1252 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.87 | ||||
| Resistance 3 (R3) | 0.86 | 0.82 | 0.85 | ||
| Resistance 2 (R2) | 0.82 | 0.80 | 0.82 | 0.85 | |
| Resistance 1 (R1) | 0.79 | 0.78 | 0.81 | 0.80 | 0.84 |
| Pivot Point | 0.75 | 0.75 | 0.76 | 0.76 | 0.75 |
| Support 1 (S1) | 0.73 | 0.73 | 0.74 | 0.73 | 0.69 |
| Support 2 (S2) | 0.68 | 0.71 | 0.69 | 0.69 | |
| Support 3 (S3) | 0.66 | 0.68 | 0.68 | ||
| Support 4 (S4) | 0.66 |
